| Erythropoietin as a neuroprotective agent. | |
| | |
MedLine Citation:
|
PMID: 21402522 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
NEONATAL NURSES ARE most familiar with recombinant er y thropoietin (EPO), epoetin alfa (Epogen, Amgen Manufacturing, Thousand Oaks, California; Procrit, Amgen, Inc., Thousand Oaks, California, for Centocor Ortho Biotech Products, LP, Raritan, New Jersey), a treatment for anemia of prematurity. Recent animal and human neonatal studies demonstrate the potential for a neuroprotective function of EPO in infants with hypoxicischemic encephalopathy (HIE).1-3 Erythropoietin has also been shown to improve functional and histologic outcome in neonatal stroke in an animal model.4 Finally, in a study of 16 premature infants, researchers found that infants with elevated EPO concentrations had higher Mental Development Index scores than those with lower EPO concentrations.5 This column discusses the physiology of EPO and describes its neuroprotective pharmacology through an exploration of the related research. |
| | |
Authors:
|
Susan Givens Bell |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Neonatal network : NN Volume: 30 ISSN: 1539-2880 ISO Abbreviation: Neonatal Netw Publication Date: 2011 Mar-Apr |
Date Detail:
|
Created Date: 2011-03-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8503921 Medline TA: Neonatal Netw Country: United States |
Other Details:
|
Languages: eng Pagination: 135-9 Citation Subset: N |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A rare cause of early neonatal death and pathologic examination of the placenta.
Next Document: Screening cold-acclimation differential expression candidate genes in the brain of common carp (Cypr...